Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide’s anti-leukemic activity

Inhibition of SREBP1 sensitizes cells to death ligands

(2015) Yanina Eberhard et al.   Oncotarget

Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia

(2011) Marko Škrtić et al.   CANCER CELL

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

A Novel Role of Dipeptidyl Peptidase 9 in Epidermal Growth Factor Signaling

(2011) T.-W. Yao et al.   MOLECULAR CANCER RESEARCH

Stem cell gene expression programs influence clinical outcome in human leukemia

(2011) Kolja Eppert et al.   NATURE MEDICINE

Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways

(2010) D. C. Hassane et al.   BLOOD

The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma

(2010) P. A. Spagnuolo et al.   BLOOD

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

(2010) G. W. Xu et al.   BLOOD

Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia

(2010) Melanie L. Sulda et al.   CANCER BIOLOGY & THERAPY

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

(2010) Yoshikane Kikushige et al.   Cell Stem Cell

Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

(2010) M. Sauve et al.   DIABETES

Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia

(2010) Andrew J. Gentles   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Parthenolide sensitizes hepatocellular carcinoma cells to trail by inducing the expression of death receptors through inhibition of STAT3 activation

(2010) Daniela Carlisi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

(2009) Mark Kirby et al.   CLINICAL SCIENCE

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Acute myelogenous leukemia

(2009) Joshua L. Shipley et al.   EXPERIMENTAL HEMATOLOGY

CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia

(2009) Camilla F. C. G. de Andrade et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

The In Vivo Expression of Dipeptidyl Peptidases 8 and 9

(2009) Denise M.T. Yu et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions

(2009) Y.N. V. Gopal et al.   MOLECULAR CANCER THERAPEUTICS

Dysregulated gene expression networks in human acute myelogenous leukemia stem cells

(2009) R. Majeti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

(2008) B. F. Burkey et al.   DIABETES OBESITY & METABOLISM

Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans

(2008) H. He et al.   DRUG METABOLISM AND DISPOSITION

Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers

(2008) Pei Hu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Preclinicalversusclinical drug combination studies

(2008) Ting-Chao Chou   LEUKEMIA & LYMPHOMA